Abbapolin inhibitors of the PLK1 PBD as Prostate Cancer Therapeutics, in vivo activity and synergy with androgen therapy
George Merhej, Gurusankar Ramamoorthy, Danda P. Chapagai, Mohammad Esfini Farahani, Yifan Kong, C.N.R. Rao, Jessy M. Stafford, Zachary T. Mack, Cassidy E Socia, S Krishna Kumari, Kristen Hogan, Niti Jan, Maria Marjorette Pena, Elmar Nurmemmedov, Ivan Babić, , Campbell McInnes
This study develops and characterizes abbapolins, non-peptidic PLK1 PBD inhibitors, showing in vivo efficacy against prostate cancer and synergy with enzalutamide.
bioRxiv · Jul 24, 2026 · PreprintCancer Biology